- Report
- August 2025
- 194 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 195 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 181 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 181 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 194 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- March 2025
- 120 Pages
Global
From €4356EUR$4,900USD£3,781GBP
- Report
- October 2025
- 371 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 385 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 375 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 553 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 383 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 141 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 565 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 170 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 387 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 392 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 166 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 244 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 193 Pages
Global
From €5200EUR$5,850USD£4,514GBP
- Report
- October 2025
- 197 Pages
Global
From €5200EUR$5,850USD£4,514GBP

Single Use Bioreactors (SUBs) are bioreactors that are designed for a single use and then disposed of. They are used in biotechnology for the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. SUBs are typically made of plastic and are pre-sterilized, eliminating the need for cleaning and sterilization between batches. This makes them ideal for rapid scale-up and production of biopharmaceuticals. SUBs also offer advantages such as reduced risk of contamination, improved process control, and reduced capital costs.
The SUB market is growing rapidly due to the increasing demand for biopharmaceuticals and the need for rapid scale-up and production. SUBs are becoming increasingly popular in the biotechnology industry due to their cost-effectiveness and convenience.
Some companies in the SUB market include Sartorius, Thermo Fisher Scientific, Merck KGaA, GE Healthcare, and Pall Corporation. Show Less Read more